b Tested in sodium chloride 0.9%.
c Tested in dextrose 5%, sodium chloride 0.9%, and Ringer’s injection, lactated.
d Tested in both dextrose 5% and sodium chloride 0.9%.
e Tested in sodium chloride 0.45%.
f Tested in dextrose 5% in Ringer’s injection, dextrose 5% in Ringer’s injection, lactated, dextrose 5%, Ringer’s injection, lactated, and sodium chloride 0.9%.
g Tested in sterile water for injection.
h Tested in bacteriostatic sodium chloride 0.9% preserved with benzyl alcohol 0.9%.
i Tested in Ringer’s injection, lactated.
j Tested in dextrose 5% in Ringer’s injection.
k Tested in dextrose 5% in Ringer’s injection, lactated, dextrose 5%, Ringer’s injection, lactated, and sodium chloride 0.9%.
l Lyophilized formulation tested.
m Refer to Appendix for the composition of parenteral nutrition solutions. TNA indicates a 3-in-1 admixture, and TPN indicates a 2-in-1 admixture.
n Tested in dextrose 5% in sodium chloride 0.45%.
o Tested in dextrose 5% in sodium chloride 0.225%.
p Tested with albumin human 0.1%.
q Test performed using the formulation WITHOUT edetate disodium.
r Piperacillin component. Piperacillin in an 8:1 fixed-ratio concentration with tazobactam.
s Quinupristin and dalfopristin components combined.
t Ceftolozane component. Ceftolozane in a 2:1 fixed-ratio concentration with tazobactam.
u Meropenem component. Meropenem in a 1:1 fixed-ratio concentration with vaborbactam.
v Ceftazidime component. Ceftazidime in a 4:1 fixed-ratio concentration with avibactam.
w Test performed using the formulation WITH edetate disodium.
x Sulbactam component. Sulbactam in a 1:1 fixed-ratio concentration with durlobactam.
y Subvisible particulate test methods include light obscuration, flow imaging microscopy, and backgrounded membrane imaging.